Drug intelligence / Profile preview

HLSC-001

Development stage: Unknown
Lead developer: Unicyte
Modality: Stem Cell Therapies → Cell Therapies
Administration: Percutaneous, Parenteral

Overview

HLSC-001 is an allogeneic human liver stem cell (HLSC) therapy developed by Unicyte AG, a subsidiary of Fresenius Medical Care. It consists of a novel population of adult stem cells derived from healthy human liver tissue. The therapy is designed to treat early-onset urea cycle disorders (UCD) by providing a source of functional hepatocytes. When injected percutaneously into the liver, HLSCs are expected to differentiate into urea-producing cells, thereby restoring ureagenesis and facilitating ammonia clearance. It is currently being evaluated as a bridging therapy for pediatric patients with enzyme deficiencies such as ornithine transcarbamylase (OTC) and carbamoyl-phosphate synthase 1 (CPS1) prior to liver transplantation.

Other names: allogeneic human liver stem cellsHLSCs

Beyond the preview

Go deeper on HLSC-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLSC-001.

Explore the full profile